Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2023.11.24
Active substance: hydroxyethyl starch | HES
Fresenius Kabi Deutschland GmbH has fulfilled the conditions set out in Annex III of the European Commission's Implementing Decision. The suspension of the affected HES-containing marketing authorizations of Fresenius Kabi Deutschland GmbH will therefore not be ordered. In the meantime, B. Braun Melsungen AG has withdrawn its HES-containing marketing authorizations. Due to the waiver, these authorizations have been deleted and can therefore no longer be suspended.
Decision of the European Commission on the suspension of marketing authorizations for infusion solutions containing hydroxyethyl starch (HES); entry into force of the suspension decision
Following the entry into force of the European Commission's decision to suspend marketing authorizations for infusion solutions containing hydroxyethyl starch (HES), Germany will use a transition period of 18 months.
On 15.04.2019, the experts were informed about the details of the programme for controlled access to medicines containing HES in order to strengthen the existing restrictions.
Due to numerous inquiries, the BfArM provides further information on the program for controlled access to drugs containing HES.
In its notice of 31 July2018, the Federal Institute for Drugs and Medical Devices (BfArM) has ruled the realisation of the corresponding implementing decision of the EU Commission C(2018) 4832 final of 17 July 2018.
The CMDh is introducing new measures in order to protect patients.
The PRAC confirms its earlier recommendation for suspension of marketing authorisation.
The BfArM issues information on the opinion of the Standing Committee for Medicinal Products for Human Use regarding HES within the European safety review in accordance with Article 107i of Directive 2001/83/EC for medicinal products containing HES
The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed the recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) to suspend the marketing authorisations of medicinal products for infusion containing HES across Europe.
In the course of the European safety review according to Article 107i of Directive 2001/83 initiated in October of 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of marketing authorisations for medicinal products for infusion containing hydroxyethyl starch (HES) in Europe.
The BfArM issues information on the initiation of a European safety review according to Article 107i of Directive 2001/83/EC regarding medicinal products containing HES. Studies show low adherence to restrictions aiming at reducing risks of kidney injury and death.
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):
Hydroxyethyl starch (HES) containing medicinal products
To the risk assessment procedure (available in German only)